(Sharecast News) - AstraZeneca is to invest $2bn in US biopharma Summit Therapeutics, the British drugs giant said on Tuesday, as it looks to broaden its oncology offering.
Under the terms of the deal, AstraZeneca will buy newly-issued equity in the New York-listed oncology specialist, giving it rights equivalent to around...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE